Preclinical development and IND milestones are often measured by speed to market, supported by toxicology evaluation, first-in-human studies, and seamless scalability. As a global leader in peptide CDMO services, PolyPeptide combines speed, flexibility, deep process knowledge, and strong process economy and control. We leverage advanced process intensification technologies such as flow chemistry, automation, PAT, and high-capacity resins to deliver sufficient API rapidly and reliably. This presentation will share results achieved with these enablers and explain why partnering with PolyPeptide is a game changer for tox and early-phase peptide manufacturing.